沙美特罗替卡松吸入剂对慢性阻塞性肺疾病Ⅲ~Ⅳ级疗效观察(3)
 |
| 第1页 |
参见附件(2769KB，3页)。
[2] Agusti AG. COPD，a multicomponent disease：implications for management [J]. Respir Med，2005，99(21)：670-682.
[3] Hogg JC，Chu F，Utokaparch S，et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease [J]. N Eng J Med，2004，350：2645-2653.
[4] Parr DG，White AJ，Bayley DL，et al. Inflammation in sputum relates to progression of disease in subjects with COPD：a prospective descriptive study [J]. Pespir Res，2006，7(12)：136.
[5] 中华医学会呼吸病学分会，慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志，2007，30(14)：8-17.
[6] Barnes NC，Qiu YS，Pavord ID，et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease [J]. Am J Respir Crit Care Med，2006，173(15)：736-743.
[7] Bourbeau J，Christodoulopoulos P，Maltais F，et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD：a randomised controlled trial [J]. Thorax，2007，62(12)：938-943.
[8] Mahler DA，Wire P，Horstman D，et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med，2002，166(9)：1084-1091.
[9] Hanania DA，Wire P，Horstman D，et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol(50 microg)combined in the discus inhaler for the treatment of COPD [J]. Chest，2003，124(16)：834-843.
[10] Calverley PA，Anderson JA，Celli B，et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J]. N Engl J Med，2007，356(11)：775-789.
[11] Zheng JP，Yang L，Wu YM，et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate(500 microg)inhalation twice daily via accuhaler in Chinese patients with COPD [J]. Chest，2007，132(22)：1756-1763.
(收稿日期：2011-08-04 本文编辑：张瑜杰)
您现在查看是摘要介绍页，详见PDF附件(2769KB，3页)。